Leerink analyst Andrew Berens downgraded Mirati Therapeutics to Market Perform from Outperform with a price target of $58, down from $78.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MRTX:
- Leerink downgrades Mirati to Market Perform as focus remains on acquisition
- Mirati Therapeutics downgraded to Hold on pending buyout at Stifel
- Mirati Therapeutics downgraded to Hold from Buy at Stifel
- Mirati Therapeutics reports Q3 EPS ($2.49), consensus ($2.83)
- Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
